Atıf İçin Kopyala
AKSU S., ŞAHİN F., Uz B., Güçlü Y. S., Atay H., Kelkitli E., ...Daha Fazla
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.22, sa.1, ss.8-14, 2012 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
22
Sayı:
1
-
Basım Tarihi:
2012
-
Doi Numarası:
10.4999/uhod.12004
-
Dergi Adı:
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.8-14
-
Anahtar Kelimeler:
Chronic myeloid leukemia, Dasatinib, Treatment dosage, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITOR, NILOTINIB FORMERLY AMN107, CHRONIC-PHASE, BCR-ABL, IMATINIB RESISTANCE, THERAPY, FAILURE, NONADHERENCE, INTOLERANCE
-
Ondokuz Mayıs Üniversitesi Adresli:
Evet
Özet
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.